secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioRestorative Therapies, Inc. (BRTX)
CIK:        0001505497
Form:       8-K
Filed at:   2021-11-08T23:59:59+00:00
Accession:  0001021771-21-000087
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioRestorative Therapies prices $23M public offering, uplists to Nasdaq; appoints CFO and new directors
--------------------------------------------------------------------------------

- Priced underwritten public offering of 2.3M units at $10/unit for gross proceeds of $23M; net proceeds ~$20.87M.
- Common stock begins trading on Nasdaq Capital Market under symbol BRTX on November 5, 2021.
- Appointed Robert E. Kristal as CFO; granted option for 10,490 shares at $13.50; also elected Patrick F. Williams and David Rosa as directors.
- Granted options to officers and directors: Alstodt and Silva each received 42,059 shares; also repriced their existing options from $47.60 to $13.50.
- Intends to use proceeds for clinical trials of BRTX-100, ThermoStem R&D, and working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/0001021771-21-000087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1505497/000102177121000087/form8kdtd110421.htm
  HTML page:      https://secwatch.observer/filing/0001021771-21-000087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer